LYONS GARY A (CIK 1123343) reported 15 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-08-19). Recent activity: Buy TVTX (5,000 shares), Sell TVTX (1,900 shares), Sell TVTX (2,600 shares), Sell TVTX (500 shares), Buy TVTX (5,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Travere Therapeutics, Inc. (TVTX) | Director | Buy | 5,000 | $87,200 |
| 2026-08-19 | Travere Therapeutics, Inc. (TVTX) | Director | Sell | 1,900 | $118,805 |
| 2026-08-19 | Travere Therapeutics, Inc. (TVTX) | Director | Sell | 2,600 | $165,100 |
| 2026-08-19 | Travere Therapeutics, Inc. (TVTX) | Director | Sell | 500 | $32,081 |
| 2026-08-19 | Travere Therapeutics, Inc. (TVTX) | Director | Buy | 5,000 | $87,200 |
| 2026-08-19 | Travere Therapeutics, Inc. (TVTX) | Director | Sell | 4,100 | $259,390 |
| 2026-08-19 | Travere Therapeutics, Inc. (TVTX) | Director | Sell | 900 | $57,470 |
| 2026-05-21 | NEUROCRINE BIOSCIENCES INC (NBIX) | Director | Buy | 1,659 | $0 |
| 2026-05-21 | Travere Therapeutics, Inc. (TVTX) | Director | Buy | 4,000 | $0 |
| 2026-04-16 | Travere Therapeutics, Inc. (TVTX) | Director | Buy | 8,000 | $130,640 |
| 2026-04-16 | Travere Therapeutics, Inc. (TVTX) | Director | Sell | 8,000 | $328,560 |
| 2025-12-04 | NEUROCRINE BIOSCIENCES INC (NBIX) | Director | Buy | 15,000 | $718,350 |
| 2025-12-04 | NEUROCRINE BIOSCIENCES INC (NBIX) | Director | Sell | 15,000 | $2.3M |
| 2025-05-22 | NEUROCRINE BIOSCIENCES INC (NBIX) | Director | Buy | 1,435 | $0 |
| 2025-05-16 | Travere Therapeutics, Inc. (TVTX) | Director | Buy | 6,500 | $0 |
Source: SEC Form 4 filings · as of 2026-08-19